Placebo-Controlled Trials Explained: Why Placebos Are Used

Medical Conditions · By Web Admin · · Updated · 10 min read
Placebo-Controlled Trials Explained: Why Placebos Are Used

Placebo-controlled trials are one of the most powerful – and most debated – research designs in medicine. Using an inert comparator (a sugar pill, a saline injection, or a sham procedure) lets researchers determine whether an observed treatment effect is due to the drug itself or to other factors like the placebo response, the natural course of the disease, or simply being in a study. But placebo controls also raise ethical questions when people with serious conditions might be assigned to receive no active treatment. Understanding placebo controlled trials – when they are appropriate, when they are not, and what participants experience – is useful for anyone weighing trial participation or trying to read research critically. This article is general educational information, not medical advice.

Why placebos are scientifically necessary

The placebo effect is real and can be substantial. People receiving inert treatments often experience genuine symptom improvement through psychological and contextual mechanisms – expectation, attention, and the structured medical interaction itself. The size of the placebo response varies by condition and outcome; in trials of pain and of depression, for example, placebo response rates are often reported in the range of roughly 30% to 50%. Without a placebo control, separating a drug’s actual effect from this response is difficult or impossible.

Beyond the placebo effect, several other factors can produce apparent improvement that is not due to the treatment being tested:

Stay ahead in healthcareThe latest happenings in the medical field — free, about monthly, no spam.
  • Natural disease course: Many conditions improve on their own over time.
  • Regression to the mean: People enrolled when symptoms are at their worst tend to drift back toward their average state regardless of treatment.
  • Hawthorne effect: Being observed or studied can itself change behavior and outcomes.
  • Co-interventions: Other care received during the trial can affect outcomes.

A placebo control accounts for all of these in the comparison group, helping isolate the treatment’s specific effect.

The randomization and blinding framework

Placebo controls are typically combined with randomization (random assignment to treatment groups) and blinding (keeping participants and/or researchers from knowing who got what). This combination – the randomized, double-blind, placebo-controlled trial – is widely regarded as a gold standard of clinical research.

The structure works because:

  • Random assignment tends to balance the groups for known and unknown factors.
  • Blinding prevents conscious or unconscious bias from influencing how outcomes are reported or assessed.
  • The placebo creates a comparison that controls for the placebo response and the natural course of the disease.

For drug approval, the FDA generally requires evidence from adequate and well-controlled trials, with placebo controls used when they are ethically appropriate. The FDA’s E10 guidance lays out the considerations for choosing a control group, including placebo, active (existing-treatment), and other designs.

The ethical foundation of a placebo-controlled trial rests on clinical equipoise – genuine uncertainty in the expert community about whether the new treatment is better than the comparator. When that honest uncertainty exists, randomizing participants is ethically defensible; when it does not, it is not.

Two safeguards apply to every properly conducted trial in this framework:

  • Informed consent. Before enrolling, participants must be told, in understandable terms, that the study is research, that they may receive a placebo, the odds of each assignment, the potential risks and benefits, the alternatives (including standard care outside the trial), and that participation is voluntary and can be withdrawn at any time.
  • Independent ethics review (IRB). An Institutional Review Board (or research ethics committee) must review and approve the protocol before it begins and monitor it over time, specifically weighing whether a placebo arm is justified and whether participants are adequately protected.

When placebo controls are ethically appropriate

Placebo controls are generally considered ethical when:

No proven effective treatment exists. For a condition without an established therapy, comparing a new treatment to placebo is the appropriate baseline.

The placebo phase is short and rescue treatment is available. For conditions with effective treatments, some trials use limited-duration placebo periods with clear provisions for participants to receive standard treatment if they worsen.

The condition is mild or self-limited. Trials in conditions such as seasonal allergies, mild headache, or short-term insomnia can more readily use placebo controls because the condition is not life-threatening and no critical care is being withheld.

Participants have refused or already failed standard treatment. If participants have exhausted standard options or declined them, a placebo comparison does not deny them effective care they would otherwise have received.

When placebo controls are problematic

Placebo controls become ethically problematic when:

An effective standard treatment exists. Withholding proven effective therapy to maintain a placebo group can cause avoidable harm. This is where the Declaration of Helsinki (below) draws a firm line – when a proven effective treatment exists, new treatments should generally be tested against that standard rather than a bare placebo.

The condition is serious or life-threatening. Trials in advanced cancer, severe heart failure, and similar conditions typically avoid placebo-only arms because the consequences of receiving no active treatment can be severe.

The trial is long enough to cause harm. Even when standard treatment is imperfect, a lengthy placebo arm can produce meaningful harm.

In these situations, modern trials commonly use active comparators or “add-on” designs, in which everyone receives the standard treatment and is then randomized to the new treatment or placebo on top of it – so no one is denied established care.

What the Declaration of Helsinki says (2024 revision)

The World Medical Association’s Declaration of Helsinki, the leading international ethics statement for research involving humans, was most recently revised in October 2024. Its provision on placebo (Section 33) sets a demanding standard: new interventions should be tested against the best proven intervention(s), and a placebo or no-treatment control is acceptable only when no proven intervention exists, or when there are compelling and scientifically sound methodological reasons for using it to establish efficacy or safety. Even then, participants who receive placebo must not be exposed to additional risks of serious or irreversible harm compared with those receiving the best proven option, and the Declaration warns that “extreme care must be taken to avoid abuse of this option.” In short, the default is comparison against the best available treatment, with placebo confined to narrow, well-justified circumstances.

Active-controlled vs placebo-controlled trials

Active-controlled trials compare a new drug against an existing approved treatment rather than an inert one. This is increasingly common where established treatments exist. Active controls answer “is the new treatment at least as good as the current standard?” rather than “does it work better than nothing?”

The trade-offs:

  • Active controls are more ethically appropriate when a proven treatment exists.
  • Placebo controls can produce cleaner statistical comparisons and sometimes require smaller trials.
  • Active-controlled non-inferiority designs are statistically more complex and depend on assumptions that must be justified.
  • Some regulatory questions are still best answered with placebo-controlled data when that is ethically possible.

What participants experience in placebo trials

If you enroll in a placebo-controlled trial, you can generally expect that:

  • You will be randomly assigned to receive either the experimental treatment or placebo.
  • You will not know which you received until the trial unblinds (often at the end).
  • The trial will continue normal monitoring and visits regardless of your assignment.
  • If you experience adverse events or your condition worsens, the protocol typically includes provisions for unblinding and providing rescue treatment.
  • At the trial’s end, you may be eligible for an open-label extension in which you receive the experimental treatment regardless of your original assignment.

The probability of receiving placebo depends on the design – often around 50% in two-arm trials, and lower in trials with several experimental arms. These details should be spelled out in the informed-consent document; ask the study team anything that is unclear before enrolling.

The placebo effect itself

The placebo effect is genuine and produces real, measurable symptom changes in many people. Proposed mechanisms include:

  • Conditioned responses based on prior medical experiences
  • Expectation of benefit that influences subjective symptoms
  • Attention and care from the medical team
  • Reduced anxiety from being in a structured medical setting

The effect tends to be strongest for subjective symptoms (pain, anxiety, sleep) and weaker for objective measures (blood pressure, blood glucose, tumor size). Because it contributes to outcomes in both the placebo and the active groups, isolating a treatment’s true effect through a placebo comparison is what makes the evidence definitive.

Open-label extensions

Many placebo-controlled trials include open-label extension phases after the controlled period ends. In these extensions, all participants – including those who received placebo – can receive the experimental treatment. Extensions provide:

  • Access to the experimental treatment for participants who had placebo
  • Longer-term safety and effectiveness data
  • An ethical bridge between the controlled trial and potential approval

If you are considering enrollment, it is reasonable to ask whether an open-label extension is included.

Sham controls in surgical and device trials

Trials of surgical procedures or devices sometimes use sham controls – simulated procedures that mimic the real one without the active intervention. Sham-controlled trials of certain procedures (for example, some studies of vertebroplasty for spinal fractures) have produced surprising results showing the procedure was not clearly better than the sham.

Sham controls are ethically more complex than drug placebos because they can involve real procedures, anesthesia, or incisions. Their use is more limited and requires extensive justification and IRB scrutiny, but they have produced important evidence about which procedures actually work.

Frequently Asked Questions

Will I get the placebo if I am in a placebo-controlled trial?

Possibly. The probability depends on the design – often about 50/50 in two-arm trials. You will not know which group you are in until the trial unblinds, usually at the end.

Can I get rescue treatment if I am doing poorly on placebo?

Most placebo-controlled trials include provisions for unblinding and providing rescue treatment if a participant’s condition deteriorates. Confirm the specifics with the trial coordinator, and read the consent form, before enrolling.

Why don’t all trials avoid placebo controls?

Placebo controls produce the cleanest evidence about whether a treatment truly works. For conditions without an established treatment, they are often necessary. Where a proven treatment exists, researchers turn to active comparators or add-on designs so no one is denied effective care.

Is the placebo effect just imagination?

No. The placebo effect produces real, measurable changes in many people – particularly in subjective symptoms like pain, anxiety, and sleep. It is a genuine phenomenon, not merely imagined.

Who decides whether a placebo arm is ethical?

An independent ethics committee – an Institutional Review Board (IRB) or research ethics committee – reviews and must approve the protocol before the trial begins, guided by principles like equipoise, informed consent, and standards such as the Declaration of Helsinki. Regulators such as the FDA also apply guidance (E10) on control-group choice.

The bottom line on placebo-controlled trials

Placebo-controlled trials are essential for distinguishing a treatment’s real effect from the placebo response, the natural course of illness, and other confounding factors. They are ethically appropriate in many situations – particularly when no proven treatment exists or the condition is mild and self-limited – and problematic when an effective standard treatment exists and the condition is serious. Modern research increasingly uses active comparators or add-on designs when ethics require it, and reserves placebo for cases where it is scientifically necessary and ethically justified, under IRB oversight and informed consent. For anyone considering a trial, understanding the odds of receiving placebo, the rescue-treatment provisions, and any open-label extension is an important part of informed consent – and questions for the study team, or your own clinician, are always appropriate.

TL;DR: Placebo-controlled trials use an inert comparator so researchers can separate a treatment’s true effect from the placebo response, natural recovery, and bias – usually paired with randomization and blinding. Ethics hinge on equipoise and not denying anyone a proven effective treatment: when a standard therapy exists, trials use active comparators or add-on designs. The WMA Declaration of Helsinki (revised 2024) allows placebo only when no proven treatment exists or there are compelling scientific reasons and no risk of serious harm, and every trial requires IRB oversight and informed consent.

Disclaimer: This article is general educational information about clinical research design and ethics, not medical advice or a recommendation about enrolling in any trial. Discuss any specific study with the research team and your own clinician.

Sources